Adaptimmune Therapeutics, an onco-immunology company developing treatments to boost the ability of a person’s own immune system to recognize and destroy cancer cells, said Friday it has adopted the name “SPEAR T-Cells” to describe its priority technology.
SPEAR is an acronym for specific peptide enhanced affinity receptor T-cells. T-cells, also known as T-lymphocytes, are subtypes of white blood cells that develop in the thymus gland and are responsible for a variety of immune system responses.
To read the full article, click here.
For more business news, visit Philadelphia Business Journal.
Copyright bizjournal
